Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...
Cipla has now entered into obesity Market with a partnership with Eli Lilly for Tirzepatide (GLP-1) is exclusive to the ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. The company also recently announced a partnership with Walmart that will expand access to Zepbound ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.
Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs ...
Zacks Investment Research on MSN
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...
Eli Lilly & Co. has joined forces with artificial intelligence chipmaker Nvidia Corp. to develop what the companies describe as the most powerful supercomputer operated by a pharmaceutical firm. The ...
Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback